Distribution and Impact of Comorbidities on Survival and Leukemic Transformation in Myeloproliferative Neoplasm-Associated Myelofibrosis: A Retrospective Cohort Study

In a retrospective study of 309 patients with myelofibrosis (MF), severe burden of comorbidities as assessed by the Adult Comorbidity Evaluation 27 (ACE-27) or Hematopoietic Cell Transplant Comorbidity Index (HCT-CI) was associated with worse overall survival. ACE-27 may be preferred for comorbidity assessment in myeloproliferative neoplasm (MPN) patients as it captures cardiovascular and venous thrombosis related morbidities better than HCT-CI.

Source: Clinical Lymphoma, Myeloma and Leukemia - June 28, 2017 Category: Hematology Authors: Justyna Bartoszko, Tony Panzarella, Caroline Jane McNamara, Anthea Lau, Aaron D. Schimmer, Andre C. Schuh, Hassan Sibai, Dawn Maze, Karen W.L. Yee, Rebecca Devlin, Vikas Gupta Tags: Original Study Source Type: research